534
Participants
Start Date
November 5, 2019
Primary Completion Date
July 23, 2020
Study Completion Date
May 14, 2021
RSV MAT 60 µg
One single dose of RSV MAT 60 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
RSV MAT 120 µg
One single dose of RSV MAT 120 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
Placebo
One single dose of placebo (NaCl solution) administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
GSK Investigational Site, Auckland
GSK Investigational Site, Soweto
GSK Investigational Site, Melbourne
GSK Investigational Site, South Brisbane
GSK Investigational Site, Wellington
GSK Investigational Site, Johnson City
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Majadahonda (Madrid)
GSK Investigational Site, Málaga
GSK Investigational Site, Marbella
GSK Investigational Site, Panama City
GSK Investigational Site, Gulfport
GSK Investigational Site, Saint-Etienne
GSK Investigational Site, Englewood
GSK Investigational Site, Clermont-Ferrand
GSK Investigational Site, St Louis
GSK Investigational Site, Metairie
GSK Investigational Site, Plano
GSK Investigational Site, Fort Worth
GSK Investigational Site, Beaumont
GSK Investigational Site, Nampa
GSK Investigational Site, Phoenix
GSK Investigational Site, Albuquerque
GSK Investigational Site, Los Angeles
GSK Investigational Site, Huntington Park
GSK Investigational Site, Halifax
GSK Investigational Site, Québec
GSK Investigational Site, Helsinki
GSK Investigational Site, Panama City
GSK Investigational Site, Barcelona
GSK Investigational Site, Burgos
Lead Sponsor
GlaxoSmithKline
INDUSTRY